α-Synuclein Aggregation in Treatment of Parkinson's Disease

Parkinson’s disease, the second most common neurodegenerative disorder worldwide, is characterized by the accumulation of protein deposits in the dopaminergic neurons. These deposits are primarily composed of aggregated forms of α-Synuclein (α-Syn). PD is a complex pathology initially associated with motor deficiencies, as a result of an acute neuronal loss in substantia nigra pars compacta (SNc), with a significant dopaminergic (DA) impairment.

Parkinsons Disease - Neurobiology and Aetiology - Neurotorium

Diagnostic and therapeutic agents that target alpha-synuclein in Parkinson's disease

Alpha Synuclein in Parkinson's Disease Diagnostics

Roles of α‑synuclein in gastrointestinal microbiome dysbiosis‑related Parkinson's disease progression (Review)

α-synuclein strains that cause distinct pathologies differentially inhibit proteasome

Small soluble α-synuclein aggregates are the toxic species in Parkinson's disease

Active alpha-synuclein proteins

Cells, Free Full-Text

Tuning the Balance between Fibrillation and Oligomerization of α-Synuclein in the Presence of Dopamine

Conformation-specific Antibodies Targeting Aggregated Forms of α-synuclein Block the Propagation of Synucleinopathy

IJMS, Free Full-Text

Intermediates of α-synuclein aggregation: Implications in Parkinson's disease pathogenesis - ScienceDirect